Clinical and angiographic efficacy of a self-expanding nitinol scent in saphenous vein graft atherosclerotic disease: The Scent Comparative Restenosis (SCORES) Saphenous Vein Craft Registry

Background The Stent Comparative Restenosis (SCORES) Saphenous Vein Graft (SVG) Registry was a multicenter, prospective registry designed to evaluate the safety and efficacy of a self expanding, nickel-titianium (nitinol), scent for de novo SVG lesions. Methods In all, 159 patients with de novo vein graft lesions greater than or equal to2.75 and less than or equal to4.25 mm in diameter and <30 mm in length underwent scenting with the Radius self-expanding stent. The primary end point was target vessel failure (TVF) at months, which was defined as a composite of procedural failure, death, myocardial infarction, or target vessel revascularization. Results Procedural success was achieved in 96.8% of patients, and the 30-day incidence of major adverse cardiac events was 2.5%. The binary rate of restenosis at 6 months was 28.6%. By 9 months, the rate of TVF was 24.5%, and the rate of major adverse cardiac events was 23.1%. The 9-month Kaplan-Meier survival rates for freedom from TVF and target lesion revasclarization were 76.0%. and 87.9%, respectively. No clinical or angiographic characteristic was predictive of restenosis. Conclusions In de nova atherosclerotic SVG disease, the use of a self-expanding, nitinol scent was associated with high initial procedural success and favorable early and intermediate outcomes. Because few studies hove examined the influence of stent composition and design in SVG disease, these findings not only slow the safety and efficacy of this self expanding scent in de novo SVG disease, but also merit further comparison with balloon-expandable scents.